Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
432 studies found for:    "Cutaneous T-cell lymphoma"
Show Display Options
Rank Status Study
1 Completed Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
2 Withdrawn Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Curcumin (Turmeric);   Behavioral: Questionnaires;   Other: Photos
3 Recruiting Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Conditions: Cutaneous T Cell Lymphoma;   Graft Versus Host Disease
Intervention:
4 Terminated Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
Conditions: Mycosis Fungoides;   Cutaneous T-Cell Lymphoma;   Neoplasms
Intervention: Drug: Romidepsin (FR901228)
5 Completed Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Panobinostat
6 Completed A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: APO866
7 Completed LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Conditions: Tumors;   Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
8 Not yet recruiting Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Micro needle array-Doxorubicin (MNA-D)
9 Completed Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
10 Recruiting Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Sirolimus 0.1% Ointment
11 Active, not recruiting Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Condition: Refractory Cutaneous T-cell Lymphoma
Intervention: Drug: bexarotene
12 Unknown  Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Lenalidomide
13 Recruiting Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: carfilzomib;   Drug: romidepsin;   Other: laboratory biomarker analysis
14 Recruiting Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
Conditions: Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: vorinostat;   Other: flow cytometry;   Other: laboratory biomarker analysis
15 Terminated O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions: Drug: O6-benzylguanine;   Drug: carmustine;   Other: laboratory biomarker analysis
16 Active, not recruiting O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions: Drug: O6-benzylguanine;   Drug: carmustine;   Other: laboratory biomarker analysis
17 Terminated Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Procedure: skin biopsy
18 Recruiting Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: silicon phthalocyanine 4;   Drug: photodynamic therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Recruiting Everolimus in Treating Cutaneous T-cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Everolimus
20 Completed A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Enzastaurin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years